Prilenia announced today that they plan to submit a Marketing Authorization Application in the EU for the use of Pridopidine in the treatment of Huntington’s Disease. According to Dr. Michael Hayden, CEO of Prilenia “Pridopidine demonstrates consistent treatment benefits across independent measures that are important to patients and families. These measures, which include day-to-day function, cognition, motor and clinical progression, are clearly evident in those who are not taking anti-dopaminergic medications (ADMs).” President of the International Huntington Association, Svein Olaf Olsen said “This is really exciting news.  We’re delighted to hear that the European Medicines Agency has been receptive to the plight of patients with Huntington’s Disease and given HD families in Europe renewed cause for optimism. We are also extremely grateful to Dr. Michael Hayden and his team for their dedication and their tireless efforts to develop a treatment for this devastating condition.”   

If approved, pridopidine could be commercially available to patients in Europe as early as 2025.

See the press release here.


Leave a Reply

Avatar placeholder

Your email address will not be published. Required fields are marked *